data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRDgwMDI3IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHoiLz48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCAzMTIuODgyaDUxMnYxMTMuNzc1SDB6Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+

data:image/svg+xml;base64,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

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+

+ New Watchlist

Benzinga Research

-

-

-

-

-

-

-

Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRDgwMDI3IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHoiLz48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCAzMTIuODgyaDUxMnYxMTMuNzc1SDB6Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+

data:image/svg+xml;base64,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

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+

Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs

Free Benzinga Pro Trial

Calendars

Analyst Ratings Calendar

Conference Call Calendar

Dividend Calendar

Earnings Calendar

Economic Calendar

Guidance Calendar

Stock Split Calendar

Trade Ideas

Free Stock Reports

Trade Idea Feed

Analyst Ratings

Unusual Options Activity

Free Newsletter

Government Trades

Short Interest

Largest Increase

Largest Decrease

Calculators

Margin Calculator

Forex Profit Calculator

100x Options Profit Calculator

-

-

-

-

-

-

-

Veracyte

(NASDAQ:VCYT)

Intraday

$19.92

0.09[0.45%]

After-Hours

$19.92

0[0.00%]

Perks Buy Compare Brokers

$19.92

0.09[0.45%]

At close: Apr 24

$19.92

0[0.00%]

After Hours: 4:03PM EDT

Q1 2024 Earnings in 13 days from now on Tue May 7th, after the market close

Overview News Earnings Guidance Dividends Analyst Ratings Insider Trades Short Interest

Latest News for Veracyte Stock (NASDAQ:VCYT)

Veracyte Stock (NASDAQ: VCYT)

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Monday, April 22, 2024

Veracyte's New Study Shows The Decipher Prostate Test Is Prognostic For Prostate Cancer Progression Among Patients Undergoing Active Surveillance
Benzinga Newsdesk - 2 days ago

Tuesday, April 16, 2024

Veracyte Announces 9 Abstracts Reinforcing The Value Of Decipher Prostate And Decipher Bladder Testing Will Be Presented At AUA 2024
Benzinga Newsdesk - Apr 16, 2024, 8:42AM

Monday, April 15, 2024

Goldman Sachs Maintains Buy on Veracyte, Lowers Price Target to $28
Benzinga Newsdesk - Apr 15, 2024, 10:33AM

Thursday, February 29, 2024

Cathie Wood's Ark Invest Dumps $17M In Coinbase Shares As The Exchange Grappled With Disruption Amid Bitcoin Rally
Benzinga Neuro - Feb 28, 2024, 11:02PM

Tuesday, February 27, 2024

Cathie Wood's Ark Invest Sheds $9.3M Worth Of Coinbase Shares Amid Bitcoin Rally — Robinhood Stock Also Sold
Benzinga Neuro - Feb 27, 2024, 10:35PM

Monday, February 26, 2024

Cathie Wood's Ark Invest Offloads $6.9M Worth of Coinbase, Robinhood Shares Each Amid Searing Bitcoin Rally — Nvidia Stock Also Shed
Benzinga Neuro - Feb 26, 2024, 10:45PM
Morgan Stanley Maintains Underweight on Veracyte, Lowers Price Target to $21
Benzinga Newsdesk - Feb 26, 2024, 11:16AM

Friday, February 23, 2024

Needham Maintains Buy on Veracyte, Raises Price Target to $33
Benzinga Newsdesk - Feb 23, 2024, 5:34AM

Thursday, February 22, 2024

Veracyte Sees FY24 Revenue $394M-$402M Vs $393.285M Est.
Benzinga Newsdesk - Feb 22, 2024, 5:17PM
Recap: Veracyte Q4 Earnings
Benzinga Insights - Feb 22, 2024, 4:55PM
Veracyte Q4 2023 Adj EPS $0.05 Beats $(0.09) Estimate, Sales $98.20M Beat $91.96M Estimate
Benzinga Newsdesk - Feb 22, 2024, 4:54PM
Earnings Scheduled For February 22, 2024
Benzinga Insights - Feb 22, 2024, 5:27AM

Wednesday, February 21, 2024

Earnings Outlook For Veracyte
Benzinga Insights - Feb 21, 2024, 12:01PM

Thursday, December 28, 2023

Cathie Wood's Ark Invest Buys Over $92M Worth Of ProShares Bitcoin ETF, Sells Coinbase, Block And Palantir Shares
Benzinga Neuro - Dec 27, 2023, 11:19PM

Wednesday, November 29, 2023

Clinical Validation Data Published In CHEST Demonstrate That Veracyte's Percepta Nasal Swab Test Improves Lung Cancer Risk Assessment For Patients With Lung Nodules
Benzinga Newsdesk - Nov 29, 2023, 8:35AM

Wednesday, November 22, 2023

Veracyte Announces Seven Posters Highlighting Clinical Value Of Decipher Prostate Genomic Testing To Be Presented At SUO 2023
Benzinga Newsdesk - Nov 22, 2023, 8:32AM

Friday, November 10, 2023

Morgan Stanley Maintains Underweight on Veracyte, Lowers Price Target to $22
Benzinga Newsdesk - Nov 10, 2023, 9:26AM

Wednesday, November 08, 2023

Needham Maintains Buy on Veracyte, Lowers Price Target to $30
Benzinga Newsdesk - Nov 8, 2023, 5:02PM

Tuesday, November 07, 2023

Veracyte Raises FY23 Revenue From $342M-$350M To $352M-$354M Vs $346.89M Est.
Benzinga Newsdesk - Nov 7, 2023, 8:31PM
Veracyte: Q3 Earnings Insights
Benzinga Insights - Nov 7, 2023, 4:35PM
Veracyte Q3 2023 Gaap EPS $(0.41) Misses $(0.15) Estimate, Sales $90.11M Beat $84.38M Estimate
Benzinga Newsdesk - Nov 7, 2023, 4:33PM
Veracyte Announces In Vitro Diagnostic Agreement With Illumina To Broaden Availability Of Its Tests For Patients Globally
Benzinga Newsdesk - Nov 7, 2023, 4:01PM
Earnings Scheduled For November 7, 2023
Benzinga Insights - Nov 7, 2023, 6:34AM

Monday, October 23, 2023

Goldman Sachs Maintains Buy on Veracyte, Lowers Price Target to $32
Benzinga Newsdesk - Oct 23, 2023, 9:07AM

Friday, October 20, 2023

The Latest Analyst Ratings for Veracyte
Benzinga Insights - Oct 20, 2023, 2:00PM
Goldman Sachs Maintains Buy on Veracyte, Lowers Price Target to $32
Benzinga Newsdesk - Oct 20, 2023, 9:54AM

Thursday, October 12, 2023

New Data Presented At CHEST 2023 Demonstrate The Clinical Utility Of Veracyte's Envisia Genomic Classifier For Patients With Interstitial Lung Disease
Benzinga Newsdesk - Oct 12, 2023, 9:17AM

Tuesday, October 10, 2023

Stephens & Co. Reiterates Overweight on Veracyte, Maintains $34 Price Target
Benzinga Newsdesk - Oct 10, 2023, 10:15AM

Wednesday, October 04, 2023

Veracyte Stock Is Volatile After-Hours - Here's Why
Ryan Gustafson - Oct 4, 2023, 4:52PM
New Data From Phase 3 Trial Further Validate Prognostic Value Of Veracyte's Decipher Prostate Genomic Classifier
Benzinga Newsdesk - Oct 4, 2023, 4:12PM

Thursday, September 28, 2023

New Data Presented At The 2023 ATA Annual Meeting Demonstrate That Veracyte's Afirma-Based Testing Can Uncover Key Molecular Hallmarks Of Thyroid Cancer
Benzinga Newsdesk - Sep 28, 2023, 4:06PM

Thursday, September 21, 2023

Veracyte Announces Novel Afirma-Based Findings That Advance Molecular Understanding Of Thyroid Cancer To Be Presented At The 2023 ATA Annual Meeting
Benzinga Newsdesk - Sep 21, 2023, 4:09PM

Wednesday, September 06, 2023

Veracyte And Gustave Roussy Announce Collaboration To Help Biopharmaceutical Companies Accelerate Development Of Novel Cancer Therapies
Benzinga Newsdesk - Sep 6, 2023, 8:15AM

Tuesday, August 22, 2023

Veracyte Announces That Findings Published In JCO Precision Oncology Suggest Potential Of Decipher GRID-Derived Gene Signatures To Predict Treatment Response In Recurrent Prostate Cancer
Happy Mohamed - Aug 22, 2023, 8:15AM

Wednesday, August 09, 2023

Morgan Stanley Maintains Underweight on Veracyte, Raises Price Target to $23
Benzinga Newsdesk - Aug 9, 2023, 11:03AM
Needham Maintains Buy on Veracyte, Raises Price Target to $35
Benzinga Newsdesk - Aug 9, 2023, 6:10AM

Tuesday, August 08, 2023

Veracyte Raises FY23 Revenue Guidance From $330M-$340M To $342M-$350M
Benzinga Newsdesk - Aug 8, 2023, 5:45PM
Veracyte Q2 EPS $(0.12) Beats $(0.14) Estimate, Sales $90.32M Beat $74.66M Estimate
Benzinga Newsdesk - Aug 8, 2023, 4:26PM
Earnings Scheduled For August 8, 2023
Benzinga Insights - Aug 8, 2023, 4:48AM

Tuesday, August 01, 2023

Veracyte, Inc. Announces Study Published In JNCI Cancer Spectrum Demonstrates Real-World Utility Of Co's Decipher Prostate Genomic Classifier In Prostate Cancer Treatment
Happy Mohamed - Aug 1, 2023, 8:18AM

Tuesday, July 25, 2023

Director At This Health Care Company Sells $118K of Stock
Benzinga Insights - Jul 25, 2023, 11:01AM

Thursday, July 20, 2023

Board Member At This Health Care Company Sells $1.59M of Stock
Benzinga Insights - Jul 20, 2023, 11:01AM

Tuesday, June 20, 2023

New Data Suggest Veracyte's Afirma Molecular Testing Capabilities Can Help Advance Scientific Understanding Of Thyroid Nodules And Cancer
Happy Mohamed - Jun 20, 2023, 8:35AM

Thursday, May 25, 2023

Veracyte Reports New Data To Be Shared At The 2023 American Society Of Clinical Oncology Annual Meeting
Benzinga Newsdesk - May 25, 2023, 5:18PM

Wednesday, May 24, 2023

New Data Presented At ATS 2023 Reinforce Clinical Utility Of Veracyte's Genomic Tests In Interstitial Lung Disease And Lung Cancer
Happy Mohamed - May 24, 2023, 9:08AM

Wednesday, May 17, 2023

Looking Into Veracyte's Return On Capital Employed
Benzinga Insights - May 17, 2023, 10:48AM

Friday, May 12, 2023

Veracyte Announces that New Data Show Use of the Prosigna Test Significantly Changed Treatment Decisions for Patients with Early-Stage Breast Cancer
Benzinga Newsdesk - May 12, 2023, 6:19AM

Monday, May 08, 2023

Stephens & Co. Reiterates Overweight on Veracyte, Maintains $30 Price Target
Benzinga Newsdesk - May 8, 2023, 8:03AM

Thursday, May 04, 2023

Recap: Veracyte Q1 Earnings
Benzinga Insights - May 4, 2023, 4:50PM
Veracyte Q1 EPS $(0.11) Beats $(0.13) Estimate, Sales $82.42M Beat $75.81M Estimate
Benzinga Newsdesk - May 4, 2023, 4:49PM

Create a Watchlist

FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.

People Also Watch

Popular Channels

PreMarket Prep
Press Releases
Analyst Ratings
News
Options
ETFs

Tools & Features

Real Time Feed
Public RSS Feeds
Submit News Tips
Blog
Embeddable Finance Widgets & Tools
Benzinga Catalyst

Partners & Contributors

Affiliate Program
Contributor Portal
Licensing & Syndication
Sponsored Content
Advertise With Us
Lead Generation & SEO

About Benzinga

About Us
Careers
In The News
Events
Contact Us

Terms & Conditions
Do Not Sell My Personal Data/Privacy Policy
Disclaimer
Service Status
Sitemap

© 2024 Benzinga | All Rights Reserved